Abstract: Embodiments disclosed herein are directed to a self-learning bladder volume monitoring system. The system can include a bladder volume (BV) system configured to measure an electrical impedance of a bladder region of a patient and determine a volume of fluid disposed therein using an impedance to bladder volume model (“By model”). Further, the system can measure a total body water (“TBW”) for the patient and modify the BV model to account for variations in TBW within the tissues surrounding the bladder providing a more accurate bladder volume measurement. The system can include a “training unit” which can include one of a user input interface, an automatic urine output monitoring system, an ultrasound system, and an intrabladder pressure system configured to verify a volume of fluid within or voided from the bladder and train the BV model.

Abstract: Disclosed herein are systems and methods for providing targeted temperature management (TTM) therapy to a patient. The TTM system can include multiple embodiments of a thermal pad including embodiments that are convertible from a first patient contact area to a second patient contact area. Embodiments of thermal pads can include pads that are expandable, extendable, and/or comprise attachable or removable portions. The TTM system can include embodiments where a second thermal pad is coupled to a first thermal pad.

Abstract: Detection devices, systems, and methods for detecting an analyte in a fluid sample are provided. The detection devices, systems, and methods can include colorimetric detection to rapidly determine the presence and/or quantity of the analyte obtained from a surface that is contaminated or suspected of being contaminated with the analyte. In one aspect, the detection device includes a sample reservoir in fluid communication with a fluid flow path. The fluid flow path includes a control well downstream of the sample reservoir, a valve assembly downstream of the control well, a reagent well downstream of the valve assembly, and a test well downstream of the reagent well. In one aspect, the reagent well includes a dried reducing agent configured to generate a gas in the presence of a detection dye and the analyte in the fluid sample.

Abstract: Disclosed herein is a system, apparatus and method directed to patient temperature control. The system can include a control module configured to provide fluid that is heated or cooled, a heating and cooling system configured to couple with the control module and receive the fluid, and a temperature sensor coupled to the control module, the temperature sensor configured to measure a body temperature of a patient and provide signals to the control module that indicate the body temperature. The system can include a neurostimulation device coupled to the control module to provide neurostimulation to the patient. The control module can include logic, stored on non-transitory, computer-readable medium that, when executed by one or more processors, causes performance of operations including generation and transmission of first instructions to the neurostimulation device causing initiation of a first neurostimulation procedure.

Abstract: Disclosed herein is an automated urinary output monitoring system including urine collection assembly that includes a first drainage tube coupled between a urinary catheter and an interim container, and a second drainage coupled between the interim container and a final container. A scale measures the weight of urine collected in the final container and a display depicts the volume of urine collected in the final container. A vacuum pump can be coupled with the final container to draw urine from the interim container into the final container, and an air vent can isolate the patient from the vacuum within the final container. The system can be configured to wirelessly transmit urine volume data to an external computing device. A gyroscope can be coupled with the scale to determine the orientation of the scale. Logic of the system can calculate urine volume and correlate with the time of day.

Abstract: Disclosed herein is a system for monitoring urine output (UO) of a patient. The system includes a UO module configured to couple with a collection container. The UO module includes (i) a frame configured for anchoring to frame rails of a bed, (ii) a load cell configured to measure a weight of UO within the container and (iii) logic stored in memory that determines volumetric UO data from the load cell and transmits the UO data across a network to an external entity. An intermediate coupling device between the collection container and the UO module is configured to couple with the collection container and inhibit decoupling from the collection container. The intermediate coupling device includes an identification device attached thereto, identification device including patient information, and the logic links the UO data to the patient information.

Abstract: A medical pad for exchanging thermal energy between a targeted temperature management (TTM) fluid and a patient is disclosed. The pad can include a fluid containing layer and a fluid conduit attached therewith via rotatable joint where the joint is configured to facilitate rotation of the fluid conduit with respect to the pad. A method of manufacturing the pad can include coupling a first member of the rotatable joint to a fluid delivery line, coupling the second member to the fluid containing layer, and inserting the first member within an opening of the second member to facilitate a snap-fit retention mechanism between first member and the second member. A method of using the pad can include rotating the fluid delivery line relative to the thermal pad via the rotatable joint when initially applying the pad to the patient or when adjusting an orientation of the pad on the patient.

Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.

Abstract: Methods and apparatus provide filtration for concentrating analytes, such as bacteria or exosomes, of a biological sample, such as blood or urine. The technology may employ membrane devices that implement one or more tangential flow filtration processes such as in stages. An example membrane device may typically include a membrane having sides and ends. The membrane may selectively permit constituent(s) of the sample to pass through while retaining other constituents at one side. An input chamber of the device may include an inlet near one end and an outlet near the other end, and that may permit a tangential flow of the sample along the first side surface, and a trans-membrane passing of constituent(s). An output chamber of the device may be configured at the second side surface to receive the passing constituents. Such devices may be provided in a kit to facilitate targeting of a desired biological analyte concentration.

Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.

Abstract: Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample.

Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.

Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.

Abstract: Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample.

Abstract: Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample.

Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.

Abstract: Provided herein are methods, systems, and devices for detecting and/or identifying one or more specific microorganisms in a culture sample. Indicator particles, such as surface enhanced Raman spectroscopy (SERS)-active nanoparticles, each having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest, can form a complex with specific microorganisms in the culture sample. Further, agitating magnetic capture particles also having associated therewith one or more specific binding members having an affinity for the one or more microorganisms of interest can be used to capture the microorganism-indicator particle complex and concentrate the complex in a localized area of an assay vessel for subsequent detection and identification. The complex can be dispersed, pelleted, and redispersed so that the culture sample can be retested a number of times during incubation so as to allow for real-time monitoring of the culture sample.